FLT3LG

FLT3LG is the cognate ligand for the FLT3 receptor and functions in dendritic cell biology and antitumor immunity by engaging FLT3 to drive dendritic cell differentiation and expansion (PMID:34835169, PMID:32363127). Its FLT3-binding module is sufficiently specific that full-length FLT3LG can serve as the extracellular targeting domain of a chimeric antigen receptor, killing FLT3-positive but not FLT3-negative cells in a manner competitively inhibited by soluble ligand (PMID:34835169). A single L27P substitution reduces bioactivity at least 10-fold and impairs FLT3 receptor recycling while preserving receptor-binding specificity, dissociating the binding and signaling-competent functions of the ligand (PMID:37108788). Beyond dendritic cells, FLT3LG acts directly on CD8+ T cells to promote proliferation and activation and synergizes with T-cell receptor stimulation, contributing to the antitumor effects of BCG immunotherapy (PMID:38213738). NK cells are a regulated cellular source of FLT3LG: IL2 signaling uniquely induces its expression, and NK cell-derived FLT3LG increases intratumoral cDC1 abundance and improves anti-PD-1 immunotherapy response (PMID:41081432).

1. 2020 Low

   Established the core mechanistic role of FLT3LG as the FLT3 ligand driving dendritic cell differentiation/expansion and tumor antigen cross-presentation, framing it as a node in anticancer immunity.

   Evidence Review/commentary citing established receptor-ligand mechanism, no new primary experiment

   PMID:32363127

   Open questions at the time

   • No new primary experimental data presented in this source
   • Does not quantify the contribution of FLT3LG to cross-presentation directly
   • Cell-intrinsic signaling consequences not addressed
2. 2021 Medium

   Demonstrated that the FLT3-binding module of FLT3LG is specific and exploitable, showing full-length FLT3LG can redirect CAR T cells to FLT3-positive targets.

   Evidence In vitro CAR T-cell cytotoxicity assay with FLT3-positive vs FLT3-negative cell lines and competitive inhibition by soluble ligand

   PMID:34835169

   Open questions at the time

   • Specificity shown only in cell lines, not in vivo
   • Does not map the binding interface residues
   • Single lab
3. 2023 Medium

   Separated FLT3LG receptor binding from downstream bioactivity by showing a single L27P mutation cripples potency and receptor recycling while preserving binding specificity.

   Evidence Recombinant CHO-produced protein, ED50 bioactivity assay, FLT3 recycling assay, CAR specificity assay

   PMID:37108788

   Open questions at the time

   • Structural basis of the recycling defect not resolved
   • Effect on natural dendritic cell expansion not tested
   • Single lab
4. 2024 Medium

   Extended FLT3LG function beyond dendritic cells by showing it acts directly on CD8+ T cells and synergizes with TCR signals, linking it to BCG immunotherapy efficacy.

   Evidence In vitro T-cell proliferation/activation assays, FLT3 inhibitor neutralization, BCG stimulation model

   PMID:38213738

   Open questions at the time

   • Whether FLT3 is expressed and signals directly on these T cells not fully resolved
   • In vivo contribution distinct from dendritic cell effects unclear
   • Single lab
5. 2026 Medium

   Identified NK cells as a cytokine-regulated source of FLT3LG, connecting IL2 signaling to intratumoral cDC1 abundance and anti-PD-1 response.

   Evidence Mouse melanoma model with NK subset analysis, IL2/IL15 stimulation, cDC1 quantification, anti-PD-1 outcomes, human dataset correlation

   PMID:41081432

   Open questions at the time

   • Mechanism of IL2-driven Flt3l transcriptional induction not defined
   • Relative contribution of NK-derived vs other-source FLT3LG not quantified
   • Single lab

• The structural determinants of FLT3LG-FLT3 engagement and the signaling pathways activated downstream in dendritic cells versus CD8+ T cells remain undefined in the available corpus.
• No structural model of the FLT3LG-FLT3 complex in the timeline
• Downstream signaling cascade not characterized
• Transcriptional regulation of FLT3LG expression beyond IL2 not mapped